GKB · NSE
GKB Ophthalmics Limited
₹67.68
-2.94% (-₹2.05)
Prev. close
₹69.73
Volume
2,440
Delivery %
87.8%
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About GKB Ophthalmics Limited
GKB Ophthalmics Limited engages in the manufacture and sale of unfinished ophthalmic lenses in India and internationally. It offers semifinished organic lenses, such as single vision, bifocal, and progressive. The company was incorporated in 1981 and is based in Mapusa, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Gaurav Gupta
Headquarters
Mapusa
Employees
156
Website
gkb.netExchange
View on NSE ↗Key stats
Market cap
₹34.11 Cr
P/E ratio (TTM)
10.5
EPS (TTM)
₹6.44
Beta (5Y monthly)
0.47
Shares float
12.30 L
EPS · quarter ended Jun 2026
₹2.00
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹56.88 Cr | ₹70.94 Cr | ₹75.48 Cr | ₹88.25 Cr | ₹108.99 Cr | ₹149.06 Cr | |
| EBITDA | ₹3.63 Cr | ₹6.00 Cr | ₹4.61 Cr | ₹2.09 Cr | ₹-1.45 Cr | ₹9.08 Cr |
| ₹-74.80 L | ₹1.94 Cr | ₹11.60 L | ₹-2.98 Cr | ₹-7.08 Cr | ₹1.22 Cr | |
| Diluted EPS | — | — | ₹-0.33 | ₹-5.58 | ₹-13.98 | ₹2.42 |
Diluted EPS has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2026 could not be independently verified against the company's own annual report: this page shows ₹1.22 Cr while the annual report gives ₹3.03 Cr (148.4% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹-1.84 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| — | — | — | ₹112.09 Cr | ₹114.50 Cr | ₹125.21 Cr | ₹132.17 Cr | |
| — | — | — | ₹11.22 Cr | ₹11.49 Cr | ₹14.50 Cr | ₹11.66 Cr | |
| Stockholders' equity | — | — | — | ₹67.30 Cr | ₹64.20 Cr | ₹56.44 Cr | ₹54.89 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-2.77 Cr | ₹4.22 Cr | ₹-3.43 Cr | ₹-3.81 Cr | |
| Investing cash flow | — | — | ₹1.43 Cr | ₹-1.71 Cr | ₹2.55 Cr | ₹9.00 Cr |
| — | — | ₹-2.19 Cr | ₹-1.64 Cr | ₹66.88 L | ₹-5.55 Cr | |
| Capital expenditure | — | — | ₹-1.21 Cr | ₹-2.08 Cr | ₹-2.15 Cr | ₹-1.03 Cr |
| End cash position | — | — | ₹2.36 Cr | ₹3.23 Cr | ₹3.02 Cr | ₹2.67 Cr |
Operating cash flow, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| GKB Ophthalmics Limited | ₹34.11 Cr | ₹67.68 | 10.5 | 0.65 | 2.3% | 0.22 | +36.8% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 25
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.